View through laparoscope of ovary of a 2.41 m 15 year old female preparing to breed this year demonstrating enlarged follicles, vesicles and expanded oviduct approximately 12 weeks before nesting season.

Small follicles starting to show reaction to stimulation are also present. (Numbers refer to descriptions in Table 1).</p

Externalized ovary of 2.68 m, 14 year old female alligator preparing to breed approximately 8 weeks prior to onset of nesting season, illustrating complex presentation of ovarian structures.

Externalized ovary of 2.68 m, 14 year old female alligator preparing to breed approximately 8 weeks prior to onset of nesting season, illustrating complex presentation of ovarian structures.</p

Quiescent ovary of a 2.29 m adult of unknown age who may breed next year showing small previtellogenic follicles and an expanded oviduct 12 weeks before nesting season.

Quiescent ovary of a 2.29 m adult of unknown age who may breed next year showing small previtellogenic follicles and an expanded oviduct 12 weeks before nesting season.</p

Classification of follicular development prior to ovulation, as well as descriptions of corpus luteum, corpus albicans, and atretic follicles in ovaries of American Alligators as observed via laparoscopy.

[See: Milnes [5], Lance [6], Guillette, Woodward [18], Uribe and Guillette [20] for descriptions of the reproductive cycle and/or histological descriptions].</p

2.25 m 12 year old female who bred last year or the year before showing a follicular scar and inactive follicles 12 weeks before nesting season.

2.25 m 12 year old female who bred last year or the year before showing a follicular scar and inactive follicles 12 weeks before nesting season.</p

Step-by-step protocol, also available on protocols.io.

Step-by-step protocol, also available on protocols.io.</p

Surgical approach to gain best access to the reproductive organs.

At least 1 to 3 scales cranial of the cranial pelvic girdle and 2 to 3 scales lateral of midline.</p

Synthesis, Modification, and Characterization of a Family of Homologues of <i>e</i><i>xo</i>-Calix[4]arene: <i>e</i><i>xo</i>-[<i>n</i>.<i>m</i>.<i>n</i>.<i>m</i>]Metacyclophanes, <i>n</i>,<i>m</i> ≥ 3

A general strategy for the preparation of the family of exo-[n.m.n.m]metacyclophanes (n,m ≥ 3) in 6-steps (starting from 2-bromoanisole) that utilizes a [2 + 2] approach to furnish the exo-metacyclophane ring in good to moderate yield is described. The soluble copper catalyst [CuBr−LiSPh−LiBr−THF] is used to efficiently couple Grignard and alkyl or ether tosylate reagents in several of the synthetic steps, including the ring construction in the final step. The exo-[n.m.n.m]metacyclophane ring is conformationally mobile on the NMR time scale, and X-ray crystallography reveals that exo-[3.3.3.3]metacyclophane 2a assumes a cone conformation, and that exo-[6.6.6.6]metacyclophane 6a assumes a chair conformation. Molecular mechanics calculations show that both conformations for each exo-metacyclophane are very similar in energy. Regiocontrol over the alkylation and acylation of the phenolic oxygens of 2b is problematic, although the preparation of the tetraacetylated 18 and alkylation of 2b with CH2BrCl to furnish the methylene-linked mono- and bis-adducts 19 and 20 are straightforward

Synthesis, Modification, and Characterization of a Family of Homologues of <i>e</i><i>xo</i>-Calix[4]arene: <i>e</i><i>xo</i>-[<i>n</i>.<i>m</i>.<i>n</i>.<i>m</i>]Metacyclophanes, <i>n</i>,<i>m</i> ≥ 3

A general strategy for the preparation of the family of exo-[n.m.n.m]metacyclophanes (n,m ≥ 3) in 6-steps (starting from 2-bromoanisole) that utilizes a [2 + 2] approach to furnish the exo-metacyclophane ring in good to moderate yield is described. The soluble copper catalyst [CuBr−LiSPh−LiBr−THF] is used to efficiently couple Grignard and alkyl or ether tosylate reagents in several of the synthetic steps, including the ring construction in the final step. The exo-[n.m.n.m]metacyclophane ring is conformationally mobile on the NMR time scale, and X-ray crystallography reveals that exo-[3.3.3.3]metacyclophane 2a assumes a cone conformation, and that exo-[6.6.6.6]metacyclophane 6a assumes a chair conformation. Molecular mechanics calculations show that both conformations for each exo-metacyclophane are very similar in energy. Regiocontrol over the alkylation and acylation of the phenolic oxygens of 2b is problematic, although the preparation of the tetraacetylated 18 and alkylation of 2b with CH2BrCl to furnish the methylene-linked mono- and bis-adducts 19 and 20 are straightforward

Overview of the Cost-effectiveness Model Structure: Treatment Phase and Post-treatment Phase.

<p>DCC indicates decompensated cirrhosis; eRVR, extended rapid virologic response; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; PR, pegylated interferon alfa-2a plus ribavirin; RGT, response-guided therapy; SVR, sustained virologic response; TVR, telaprevir. a Treatment-naïve patients received no prior therapy for HCV, including interferon or peginterferon monotherapy; prior relapsers had HCV RNA undetectable at the end of treatment with peginterferon alfa and ribavirin but HCV RNA detectable within 24 weeks of treatment follow-up; prior partial responders had greater than or equal to a 2-log10 reduction in HCV RNA at week 12, but did not achieve HCV RNA undetectable at the end of treatment with peginterferon alfa and ribavirin; prior null responders had less than a 2-log10 reduction in HCV RNA at week 12 of treatment with peginterferon alfa and ribavirin. b Although not eligible for RGT in REALIZE, prior relapsers were eligible for RGT in the model (i.e., they could discontinue treatment early if eRVR was achieved), per the TVR prescribing information (INCIVEK, 2012) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0090295#pone.0090295-Vertex1" target="_blank">[15]</a>. c Transition probabilities between health states differed depending on achievement of SVR. Specifically, patients with SVR and with no or mild fibrosis (F0–F2) experienced no further liver deterioration. Patients with SVR and with advanced fibrosis (F3–F4) were at continuing risk of liver deterioration, but at lower probabilities than patients without SVR. ^d HCV-related death could occur only from health states DCC, HCC, and liver transplant.</p